{"id":781844,"date":"2023-09-05T09:38:29","date_gmt":"2023-09-05T13:38:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/"},"modified":"2023-09-05T09:38:29","modified_gmt":"2023-09-05T13:38:29","slug":"inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/","title":{"rendered":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

\n The authorization provides approval for the Company to expand\u00a0the ongoing<\/strong>\u00a0Phase 2<\/strong>\u00a0trial of XPro<\/strong>\u2122<\/strong> in patients with\u00a0early Alzheimer\u2019s\u00a0disease\u00a0to the U.K.<\/strong><\/p>\n

\n Boca Raton, Florida, Sept. 05, 2023 (GLOBE NEWSWIRE) — <\/strong>
\n
\n
\n INmune Bio, Inc.<\/u>
\n <\/strong>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, today received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 trial in Early Alzheimer\u2019s disease (AD) with XPro\u2122. The U.K. CTA is part of the Company\u2019s international clinical development strategy for XPro\u2122 in patients with early AD. The trial is also enrolling patients in Australia and Canada.<\/p>\n

The AD02 Phase 2 clinical trial is a global, multi-center, randomized clinical study in patients diagnosed with early Alzheimer’s disease. In a prior Phase I open-lab trial, INmune Bio met all primary and secondary endpoints. AD patients treated with XPro\u2122 exhibited significant reductions in neuroinflammation, improved axonal integrity, and improved synaptic function. Using sophisticated MRI imaging techniques that allow a \u201cvirtual biopsy\u201d of the brain, treatment of XPro\u2122 demonstrated improvements in the structural integrity of both gray and white matter in the brain.<\/p>\n

“We believe that the United Kingdom serves as an optimal setting for conducting clinical studies on Alzheimer’s disease. The medical community in the region is highly sophisticated, and patients, along with their dedicated caregivers, exhibit strong motivation to Alzheimer\u2019s trials. Moreover, the government recognizes that Alzheimer\u2019s represents not only a medical challenge but also an economic concern,” remarked Dr. RJ Tesi, CEO of INmune Bio. “We firmly believe that establishing clinical study sites for AD02 in the UK will accelerate patient enrollment in this vital clinical trial, offering novel treatment options to individuals grappling with this debilitating condition.”<\/p>\n

The UK has one of the highest rates of AD in the western world (47<\/u><\/a>\u00a0cases<\/u><\/a>\u00a0per 100,000 patients) with almost\u00a0one<\/u><\/a>\u00a0million patients<\/u><\/a>\u00a0 diagnosed with dementia. In 2021, the estimated cost of dementia care in the UK was \u00a325 billion. Dementia is expected to be the costliest health condition by\u00a02030<\/u><\/a> and the UK is not in a unique situation. Globally, the number of people living with dementia is projected to triple by 2050. As a result of the quality of its medical research and the presence of the National Health Service, the UK plays an important role in advancing therapies for AD.<\/p>\n

\n About XPro<\/strong>\n <\/p>\n

XPro\u2122 (XPro1595, pegipanermin) is a next-generation selective inhibitor of tumor necrosis factor (TNF) that is currently in clinical trials and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro\u2122 could potentially have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation, decreasing neurodegeneration while improving synaptic function and promoting remyelination. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit\u00a0this section of the INmune Bio\u2019s website<\/u><\/a>.<\/p>\n

\n About INmune Bio, Inc.<\/strong>\n <\/p>\n

\n
\n
\n INmune<\/u>
\n <\/strong>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>
\n
\n
\n Bio<\/u>
\n <\/strong>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/a>
\n
\n
\n Inc<\/u>
\n <\/strong>
\n <\/a>
\n
\n .<\/u>
\n <\/a>\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03\u2122), Early Alzheimer\u2019s disease, and treatment-resistant depression (XPro\u2122). The Natural Killer Cell Priming Platform includes INKmune\u2122 developed to prime a patient\u2019s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio\u2019s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit\u00a0www.inmunebio.com<\/u><\/strong><\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.\u00a0 Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03\u2122, XPro1595 (XPro\u2122), and INKmune\u2122 are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.<\/p>\n

\n INmune Bio Contact:<\/strong>\n <\/p>\n

David Moss, CFO
(858) 964-3720
info@inmunenbio.com<\/u><\/a><\/p>\n

\n Investor Contact:<\/strong><\/p>\n

Jason Nelson
Core IR
(516) 842-9614 Ext: 823<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The authorization provides approval for the Company to expand\u00a0the ongoing\u00a0Phase 2\u00a0trial of XPro\u2122 in patients with\u00a0early Alzheimer\u2019s\u00a0disease\u00a0to the U.K. Boca Raton, Florida, Sept. 05, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. \u00a0 (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, today received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 trial in Early Alzheimer\u2019s disease (AD) with XPro\u2122. The U.K. CTA is part of the Company\u2019s international clinical development strategy for XPro\u2122 in patients with early AD. The trial is also enrolling patients in Australia and Canada. The AD02 Phase 2 clinical trial … <\/p>\n

Continue reading “INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781844","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nINmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The authorization provides approval for the Company to expand\u00a0the ongoing\u00a0Phase 2\u00a0trial of XPro\u2122 in patients with\u00a0early Alzheimer\u2019s\u00a0disease\u00a0to the U.K. Boca Raton, Florida, Sept. 05, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. \u00a0 (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, today received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 trial in Early Alzheimer\u2019s disease (AD) with XPro\u2122. The U.K. CTA is part of the Company\u2019s international clinical development strategy for XPro\u2122 in patients with early AD. The trial is also enrolling patients in Australia and Canada. The AD02 Phase 2 clinical trial … Continue reading "INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-05T13:38:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease\",\"datePublished\":\"2023-09-05T13:38:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/\"},\"wordCount\":1035,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/\",\"name\":\"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==\",\"datePublished\":\"2023-09-05T13:38:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease - Market Newsdesk","og_description":"The authorization provides approval for the Company to expand\u00a0the ongoing\u00a0Phase 2\u00a0trial of XPro\u2122 in patients with\u00a0early Alzheimer\u2019s\u00a0disease\u00a0to the U.K. Boca Raton, Florida, Sept. 05, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. \u00a0 (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, today received authorization of its Clinical Trial Application (CTA) by the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 trial in Early Alzheimer\u2019s disease (AD) with XPro\u2122. The U.K. CTA is part of the Company\u2019s international clinical development strategy for XPro\u2122 in patients with early AD. The trial is also enrolling patients in Australia and Canada. The AD02 Phase 2 clinical trial … Continue reading \"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-05T13:38:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease","datePublished":"2023-09-05T13:38:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/"},"wordCount":1035,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/","name":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==","datePublished":"2023-09-05T13:38:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTY5NyM1Nzk2MTQ0IzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-approval-of-clinical-trial-application-by-the-u-k-medicines-and-healthcare-products-regulatory-agency-for-phase-2-clinical-trial-in-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781844"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781844\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}